If you have been reading about freeze-thaw cycle and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-13. Numbers and descriptions here follow the published literature rather than marketing material.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
== Diagnosis == This disorder can be suspected by symptoms, although diagnosis can be confirmed by a genetic testing. Also, diagnosis is usually made after first episode of life-threatening symptoms (such as arrhythmia).
== Clinical trials == On 7 March 2024, the company announced the results from the Phase I trial of the pill form of amycretin. In January 2025, the company announced the results of its 1B/2A trial. The trial investigated safety, tolerability, and pharmacokinetics following weekly subcutaneous administration in 125 patients. Treatment duration was up to 36 weeks. Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecast the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.
== Sources == Bulletins of the Information Bureau of the People's Union for the Defense of the Motherland and Freedom Savinkov, Boris. The Fight Against the Bolsheviks // Russian Foreign Literature. Anthology in Six Volumes. Moscow: Kniga, 1990. Vol. 1, Book 2. The Union for the Defense of the Homeland and Freedom and the Yaroslavl Rebellion of 1918 // Proletarian Revolution, 1923, no. 10. Klementyev, V. F. In Bolshevik Moscow (1918–1920). Moscow: Russkiy Put, 1998. Korovin, V. V.; Rusanov, E. P. Boris Savinkov's Case // History of the Soviet Union, 1967, no. 6, pp. 143–155. Golinkov, D. L. The Collapse of the Enemy Underground. Moscow, 1971. Gopper, Karl. Four Collapses: Memoirs of General Gopper. Riga, 1920. Jekabsons, E.; Ščerbinskis, V. Participation of Latvians in White Military Forces During the Russian Civil War 1917–1920. Riga: Journal of the Latvian Institute of History, 1997. Shentalinsky, Vitaly. "His Among His Own. Savinkov in the Lubyanka." New World, no. 7 (1996).
=== Fourth Republic === June 27, 1947: Decree creating the medical code of ethics; it includes provisions on therapeutic abortion. November 1947: Germaine Poinso-Chapuis becomes France's first female minister, for Public Health and Population; the second female minister in the country will be Simone Veil in 1974. November 5, 1947: Decree implementing the April 24, 1946, law establishing a sanitary and social registry of prostitution. September 1, 1948: Law modifying and codifying legislation on relations between landlords and tenants or occupants of residential or professional premises and establishing housing allowances. August 11, 1950: Law publishing ILO Convention No. 3 (adopted on November 29, 1919) and authorizing its ratification; this convention concerns the employment of pregnant and newly delivered women. October 15, 1951: Decree on the status of female military personnel. December 10, 1952: Law authorizing the ratification of ILO Convention No. 100, concerning "equal remuneration for men and women for work of equal value." May 17, 1954: Decree on the family record book: contents and definitions of the records and extracts to be included. August 6, 1955: Law setting the supplementary budget for agricultural family benefits for fiscal years 1955 and 1956; notably establishes a "housewife allowance," granted to the "head of household" under certain conditions. November 28, 1955: Decree on the medical code of ethics, modifying the previous one.
=== Approval ratings === In a survey conducted by Ipespe/Febraban and released in February 2023, Lula's third government was rated as good or excellent by 40% of Brazilians, regular by 27%, and bad or terrible by 28%, while 5% did not respond. In the following month, between the 2nd and 6th, Ipec conducted an analysis that was released on the 19th; in it, 41% of Brazilians rated the government as "good or excellent", 30% considered the administration "regular", and 24% thought it was "bad or terrible"; 5% did not know or preferred not to respond. In this way, Lula began his third term with higher approval than his predecessor, Jair Bolsonaro, who in March 2019 was considered "good or excellent" by 34%. Regarding confidence in Lula, 53% of the population said they trusted him, while 43% stated that they did not trust him and 4% preferred not to express an opinion. Finally, the survey found that the president's way of governing had the approval of 57% of Brazilians. On 29 and 30 March, Datafolha interviewed 2,028 people in 126 municipalities, and the Lula government was rated as excellent or good by 38%, regular by 30%, and bad or terrible by 29% of respondents. On 23 May, according to a new survey, 54% of respondents approved of the government, while 39% of respondents disapproved of the government. In June 2023, according to a new Ipec survey, the Lula government had the approval of 37% of the population, while 32% considered it regular, 28% disapproved of it, and 3% did not know how to answer.
Sources: en.wikipedia.org
=== Phase 1 === AZD-4041 – orexin OX1 receptor antagonist – opioid-related disorders BI-1356225 – ghrelin O-acyltransferase (GOAT) inhibitor – opioid-related disorders Cebranopadol (GRT-6005; PRK-101; TRN-228) – μ-opioid receptor agonist, nociceptin receptor agonist – substance-related disorders CSX-1004 – monoclonal antibody against fentanyl – opioid-related disorders Dimethyltryptamine/harmine (DMT/harmine; RE-01) – combination of dimethyltryptamine (DMT) (serotonin 5-HT2A receptor agonist and serotonergic psychedelic) and harmine (monoamine oxidase inhibitor (MAOI) and other actions) – cocaine-related disorders DPI-125 (MCP-201) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor agonist – opioid-related disorders Ibuprofen/ketotifen (SJP-005) – combination of ibuprofen (cyclooxygenase (COX) inhibitor/NSAID) and ketotifen (histamine H1 receptor antagonist, other actions) – opioid-related disorders Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – opioid-related disorders KNX-100 (SOC-1) – oxytocin-like drug / indirect oxytocin receptor modulator – opioid-related disorders, substance-related disorders Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – cocaine-related disorders MEB-1170 – μ-opioid receptor biased agonist – opioid-related disorders Mebufotenin (5-MeO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, and serotonergic psychedelic – substance use disorders MST-01 – undefined mechanism of action – smoking withdrawal Nalmefene (AV-104; TH-104) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Naltrexone implantable pellets (BICX-102, BICX-104) – opioid receptor antagonist – alcoholism, opioid-related disorders, substance-related disorders Nezavist (DCUK-OEt) – peripherally selective GABAA receptor positive allosteric modulator (etomidate site) – alcoholism Noribogaine (DMX-1001) – various actions – alcoholism NRS-033 (nalmefene prodrug) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders OMS-527 (OMS-182399; OMS527) – phosphodiesterase PDE7 inhibitor – cocaine-related disorders Psilocybin (MLS-101/MLS101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – opioid-related disorders Smoking cessation therapeutics - Astraea Therapeutics – nicotinic acetylcholine receptor antagonists – smoking withdrawal SXC-2023 – cystine/glutamate transporter (SLC7A11) – cocaine-related disorders Tezampanel (LY-293558; NGX-424; PRN-001-01) – ionotropic glutamate AMPA and kainate receptor antagonist – opioid-related disorders Zabaglurant (Heptares 25; HTL-0014242; HTL14242; TMP-301) – metabotropic glutamate mGlu5 receptor negative allosteric modulator – cocaine-related disorders, substance-related disorders
The valley is home to a great variety of wildlife including deer, foxes, and the occasional coyote, while the river hosts salmon and catfish. The Rouge River Valley forms a part of Rouge National Urban Park, a national urban park situated along the eastern portion of Scarborough, and its neighbouring municipalities. Along the shore of Lake Ontario is the earthen escarpment formation known as the Scarborough Bluffs. The Bluffs are about 14 kilometres (8.7 mi) long, and reach heights of more than 60 metres (200 ft) in places. They are part of a much larger formation known as the Iroquois Shoreline, most of which is located somewhat further inland. The Iroquois Shoreline marks the extent of a prehistoric lake, Glacial Lake Iroquois, whose level was quite a bit higher than present-day Lake Ontario's. It shrank in size at the close of the last ice age. Erosion has been a problem along the Scarborough Bluffs. Properties located near the brink have been abandoned, and houses condemned, as the brink wears back away from the lake. Since the 1980s, large areas of beach at the base of the Bluffs have been reinforced with limestone breakwaters and construction rubble infilling.
== Standard, ensign and coat of arms == After the personal union with the United Kingdom ended in 1837 with the accession of Queen Victoria, Hanover kept the British royal arms and standard, only introducing a new Crown, after the British model. The centre of this coat of arms and royal standard included the original arms of Hanover, which consisted of the two lions of the Brunswick, the rampant lion with hearts of Lüneburg and the horse of Hanover, surmounted by the Imperial Crown of the Holy Roman Empire for the Holy Roman office of Archbannerbearer/Archtreasurer. As Hanover was no longer ruled by the British monarchs, the arms of Hanover were simultaneously removed from the British coat of arms and royal standard, so it was no longer identical with that of the Kingdom of Hanover.
Thionyl chloride is a component of lithium–thionyl chloride batteries, where it acts as both the electrolyte and the positive electrode (in batteries: cathode) with lithium forming the negative electrode (anode). The overall discharge reaction is as follows:
Sources: en.wikipedia.org
Higher chemical stability (crucial for biomedical applications) Narrow size distribution (crucial for biomedical applications) Higher colloidal stability since they do not magnetically agglomerate Magnetic moment can be tuned with the nanoparticle cluster size Retained superparamagnetic properties (independent of the nanoparticle cluster size) Silica surface enables straightforward covalent functionalization Magnetic nanoparticals have also be coated with a molecularly imprinted polymer which adds a specific recognition element to the particles, enabling them to be used to specifically capture target molecules of interest.
==== Selective serotonin reuptake inhibitors (SSRIs) ==== Paroxetine (Dropax, Paxil, Seroxat, Serestill) – selective serotonin reuptake inhibitor (SSRI) [64] [65] Sertraline (Lustral, Zoloft) – selective serotonin reuptake inhibitor (SSRI) [66]
== Legality == AH-7921 was made a Prohibited Substance (Schedule 9 of the Standard for the Uniform Scheduling of Medicines and Poisons) in Australia in May 2014. Although this amendment was repealed in June 2014, which simply means the amendment document ceases, but the actual scheduling is permanent as part of the main document (all SUSMP amendments cease after a few weeks). It may, however, still be a banned import. AH-7921 has been illegal to distribute in Israel since December 2013. In the UK, AH-7921 was included as a Class A drug in January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014. In Brazil, AH-7921 has been an illegal drug since May 2015. As of October 2015 AH-7921 is a controlled substance in China. AH-7921 is banned in the Czech Republic. In the United States, AH-7921 was placed into Schedule I of the Controlled Substances Act on May 16, 2016, due to its lack of medical use. Furthermore, any person who wishes to manufacture, distribute, import, export, research, and educate using the substance, must be registered by the Drug Enforcement Administration. The Canadian Controlled Drugs and Substances Act was amended in 2016 to include the substance as a Schedule I substance. Possession without legal authority can result in maximum 7 years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May, 2016 to classify AH-7921 as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug in Canada.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.